Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward J Carr

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
BMJ Open|January 31, 2023
Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study, Edward Pk Parker, John Tazare, et al.
Ebiomedicine|June 11, 2026
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergenceRuth Harvey, Ceilidh Welsh, Alexander Mp Byrne, et al.
Nature Genetics|March 22, 2016
Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetesJames Dooley, Lei Tian, Susann Schonefeldt, et al.
Mbio|September 1, 2023
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH studyIsabel Neale, Mohammad Ali, Barbara Kronsteiner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
The Journal of Infection|September 11, 2022
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN studyAna Atti, Ferdinando Insalata, Edward J Carr, et al.
The Lancet. Infectious Diseases|December 9, 2023
SARS-CoV-2 mucosal neutralising immunity after vaccinationEdward J Carr, Guilia Dowgier, David Greenwood, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
BMJ Open|January 31, 2023
Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study, Edward Pk Parker, John Tazare, et al.
Ebiomedicine|June 11, 2026
Assessment of human immunity to A/H3N2 influenza subclade K during 2025 emergenceRuth Harvey, Ceilidh Welsh, Alexander Mp Byrne, et al.
Nature Genetics|March 22, 2016
Genetic predisposition for beta cell fragility underlies type 1 and type 2 diabetesJames Dooley, Lei Tian, Susann Schonefeldt, et al.
Mbio|September 1, 2023
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH studyIsabel Neale, Mohammad Ali, Barbara Kronsteiner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2023
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike ProteinVinit Upasani, Katie Townsend, Mary Y Wu, et al.
The Lancet. Infectious Diseases|June 8, 2023
Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infectionEdward J Carr, Mary Y Wu, Joshua Gahir, et al.
The Journal of Infection|August 23, 2025
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responsesGift Ahimbisibwe, David Greenwood, Katalin Andrea Wilkinson, et al.
The Journal of Infection|September 11, 2022
Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN studyAna Atti, Ferdinando Insalata, Edward J Carr, et al.
The Lancet. Infectious Diseases|December 9, 2023
SARS-CoV-2 mucosal neutralising immunity after vaccinationEdward J Carr, Guilia Dowgier, David Greenwood, et al.
Plos One|March 21, 2024
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination historyHermaleigh Townsley, Joshua Gahir, Timothy W Russell, et al.
Pageof 6